19 results
6-K
EX-99
BLRX
Bioline Rx Ltd
6 May 24
Current report (foreign)
7:14am
.
Embryo-fetal Toxicity: Based on its mechanism of action, APHEXDA can cause fetal harm. Advise pregnant women of the potential risk to the fetus. Verify
6-K
EX-99.1
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
can cause fetal harm. Advise pregnant women of the potential risk to the fetus. Verify pregnancy status in females of reproductive potential prior
6-K
EX-1
BLRX
Bioline Rx Ltd
16 Feb 24
Current report (foreign)
7:07am
women of the potential risk to the fetus. Verify pregnancy status in females of reproductive potential prior to initiating treatment with APHEXDA
6-K
EX-99
BLRX
Bioline Rx Ltd
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
cause fetal harm. Advise pregnant women of the potential risk to the fetus. Verify pregnancy status in females of reproductive potential prior
20-F/A
xxx 759pw7siqg
23 Mar 15
Annual report (foreign) (amended)
12:00am
424B3
3rprln5kvnlxrif
8 Aug 13
Prospectus supplement
12:00am
424B3
h8ujtrjw 658t3brqmj
15 Oct 12
Prospectus supplement
12:00am
F-1
pxxy4el3b1w9ufcg31k
2 Oct 12
Registration statement (foreign)
12:00am
424B3
97xkzbx6pl5c
28 Mar 12
Prospectus supplement
12:00am
20-F
uo5y6ke8lp
22 Mar 12
Annual report (foreign)
12:00am
20FR12B/A
1bjokibfn n23hdu
15 Jul 11
Initial registration of securities (foreign private issuers) (amended)
12:00am
20FR12B
z7twdpa0 u12nah
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
20FR12B
EX-4.17
8cmpo26n87 dk
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
F-1
EX-10.17
xi15yt6uway7h
24 Sep 10
Registration statement (foreign)
12:00am
F-1
l5uhoh03c g1ymk30o
24 Sep 10
Registration statement (foreign)
12:00am
- Prev
- 1
- Next